Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2324-2332

  Soria, J C ^a   Massard, C ^a   Le Chevalier, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Clinical trials; End point determination; Non small cell lung cancer; NSCLC; Overall survival; Progression free survival

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ABIRATERONE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; TUMOR GROWTH; VALIDATION PROCESS; VALIDATION STUDY;

EID: 78649478110     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq204     Document Type: Review

References (100)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
3. Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15(16): 5267-5273.
4. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304(5676): 1497-1500.
5. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27(26): 4247-4253.
6. Lacroix L, Commo F, Soria JC. Gene expression profiling of non-small-cell lung cancer. Expert Rev Mol Diagn 2008; 8(2): 167-178.
7. Panani AD, Roussos C. Cytogenetic and molecular aspects of lung cancer. Cancer Lett 2006; 239(1): 1-9.
8. Amarasena IU, Walters JA, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2008; (4): CD006849.
9. Bayman NA, Blackhall F, Jain P et al. Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. Clin Lung Cancer 2008; 9(2): 92-101.
10. Berhoune M, Banu E, Scotte F et al. Therapeutic strategy for treatment of metastatic non-small cell lung cancer. Ann Pharmacother 2008; 42(11): 1640-1652.
11. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359(13): 1367-1380.
12. Mutti A. Molecular diagnosis of lung cancer: an overview of recent developments. Acta Biomed 2008; 79(Suppl 1): 11-23.
13. Federal Drug Administration. Guidance for Industry. Cancer Drug and Biological Products-Clinical Data in Marketing Applications. Rockville, MD: US Department of Health and Human Services 2001.
14. Federal Drug Administration. Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville, MD: US Department of Health and Human Services 2007.
15. Oncology STAT 2009. FDA Will Revisit Appropriate Use of PFS Endpoints at Advisory Committee. http://www.oncologystat.com/news-and-viewpoints/news/FDA_Will_Revisit_Appropriate_Use_of_PFS_Endpoints_at_Advisory_Committee.html. (16 September 2009, date last accessed).
16. Committee for Medical Products for Human Use. Guideline on the Evaluation of Anticancer Medicinal Products in Man. London, UK: EMEA CPMP/EWP/205/95 /Rev 3/Corr 2. 2005.
17. Committee for Medical Products for Human Use. Appendix 1 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man. London, UK: EMEA CPMP/EWP/205/95/Rev 3. 2008.
18. Miksad RA, Zietemann V, Gothe R et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 2008; 24(4): 371-383.
19. Sherrill B, Amonkar M, Wu Y et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008; 99(10): 1572-1578.
20. Di LA, Bleiberg H, Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 2003; 21(10): 2045-2047.
21. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer 2005; 93(11): 1215-1221.
22. Beckman M. More clinical cancer treatments judged by progression-free rather than overall survival. J Natl Cancer Inst 2007; 99(14): 1068-1069.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
24. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247.
25. Schwartz LH, Bogaerts J, Ford R et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009; 45(2): 261-267.
26. Yu RX, Holmgren E. Endpoints for agents that slow tumor growth. Contemp Clin Trials 2007; 28(1): 18-24.
27. Panageas KS, Ben-Porat L, Dickler MN et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007; 99(6): 428-432.
28. Niimi M, Yamamoto S, Fukuda H et al. The influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A). Jpn J Clin Oncol 2002; 32(1): 19-26.
29. Buyse M, Molenberghs G, Burzykowski T et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1(1): 49-67.
30. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009; 27(17): 2874-2880.
31. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8(4): 431-440.
32. Buyse M, Burzykowski T, Michiels S, Carroll K. Individual- and trial-level surrogacy in colorectal cancer. Stat Methods Med Res 2008; 17(5): 467-475.
33. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25(33): 5218-5224.
34. Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol 2009; 27(35): 5958-5964.
35. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112(3): 533-543.
36. Guarneri V, Frassoldati A, Bruzzi P et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 2008; 8(5): 453-456.
37. Paridaens RJ, Dirix LY, Beex LV et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26(30): 4883-4890.
38. Di LA, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26(34): 5544-5552.
39. Goss P, Bondarenko IN, Manikhas GN et al. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol 2007; 25(31): 4961-4966.
40. Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 2009; 20(3): 460-464.
41. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008; 26(12): 1987-1992.
42. Louvet C, de GA, Tournigand C et al. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001; 91(11): 2033-2038.
43. Fountzilas G, Zisiadis A, Dafni U et al. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Oncology 2000; 58(3): 227-236.
44. Popov I, Carrato A, Sobrero A et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 2008; 44(15): 2204-2211.
45. Recchia F, Candeloro G, Necozione S et al. Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am J Clin Oncol 2008; 31(4): 323-328.
46. Wilke H, Glynne-Jones R, Thaler J et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; 26(33): 5335-5343.
47. Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol 2004; 15(4): 545-549.
48. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22(2): 229-237.
49. Giusti RM, Cohen MH, Keegan P, Pazdur R. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. Oncologist 2009; 14(3): 284-290.
50. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-2111.
51. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
52. Kane RC, Farrell AT, Saber H et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12(24): 7271-7278.
53. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25(30): 4722-4729.
54. Cloughesy TF, Prados MD, Wen PY et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 2009; 26(Suppl): (Abstr 2010).
55. Attard G, Sarker D, Reid A et al. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006; 95(7): 767-774.
56. Halabi S, Vogelzang NJ, Ou SS et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009; 27(17): 2766-2771.
57. Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009; 21(3): 260-265.
58. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther 2007; 7(10): 1423-1437.
59. Kelly K, Huang C. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol 2008; 3(6): 664-673.
60. Gettinger S. Targeted therapy in advanced non-small-cell lung cancer. Semin Respir Crit Care Med 2008; 29(3): 291-301.
61. Herbst RS, Sandler A. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 2008; 13(11): 1166-1176.
62. Manegold C. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2008; 8(5): 689-699.
63. Wheatley-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 2008; 3(10): 1173-1184.
64. Hanna N, Lilenbaum R, Ansari R et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24(33): 5253-8.
65. Robert F, Blumenschein G, Herbst RS et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005; 23(36): 9089-9096.
66. Thienelt CD, Bunn PA Jr, Hanna N et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005; 23(34): 8786-8793.
67. Rosell R, Robinet G, Szczesna A et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008; 19(2): 362-369.
68. Butts CA, Bodkin D, Middleman EL et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007; 25(36): 5777-5784.
69. Ettinger DS. Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 2009 Sep 25. [Epub ahead of print].
70. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373(9674): 1525-1531.
71. Crawford J, Swanson P, Prager D. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis. Eur J Cancer 2005; 3(Suppl 2): 324.
72. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2004; 22(11): 2184-2191.
73. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-2550.
74. Manegold C, von Pawel J, Zatloukal P. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous nonsmall cell lung cancer (NSCLC) BO17704. J Clin Oncol 2007 2007 ASCO Annual Meeting Proceedings Part I 25(Suppl): (Abstr LBA 7514).
75. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-132.
76. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25(12): 1545-1552.
77. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23(25): 5892-5899.
78. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23(11): 2544-2555.
79. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21(12): 2237-2246.
80. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290(16): 2149-2158.
81. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366(9496): 1527-1537.
82. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22(5): 777-784.
83. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22(5): 785-794.
84. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372(9652): 1809-1818.
85. Hahn O, Salgia R. Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem 2007; 7(6): 633-642.
86. Liu B, Barrett T, Choyke P et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(Suppl 18): 17119.
87. Gatzemeier U, Blumenschein G, Fossella FV et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006; 24(18S): 7002.
88. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26(4): 650-656.
89. Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009; 27(15): 2523-2529.
90. Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25(27): 4270-4277.
91. Yun-San YA, Yuen-Yuen OE, Chow LW. Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs 2008; 17(4): 583-591.
92. Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009; 8(1): 17-25.
93. Wong DW, Leung EL, So KK et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115(8): 1723-1733.
94. Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol 2008; 3(6 Suppl 2): S164-S170.
95. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008; 13(Suppl 1): 5-13.
96. Saloustros E, Georgoulias V. Docetaxel in the treatment of advanced non-smallcell lung cancer. Expert Rev Anticancer Ther 2008; 8(8): 1207-1222.
97. Tieu BH, Sanborn RE, Thomas CR Jr. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement. Thorac Surg Clin 2008; 18(4): 403-415.
98. Morabito A, Piccirillo MC, Falasconi F et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009; 14(4): 378-390.
99. Di CF, Mazzoni F, Micol MM et al. Bevacizumab in non-small cell lung cancer. Drugs 2008; 68(6): 737-746.
100. Mandrekar SJ, Hillman SL, Allen Ziegler KL et al. Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): a North Central Cancer Treatment Group (NCCTG) investigation. J Clin Oncol 2008; 26(Suppl 20): 8021.